Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume -, Issue -, Pages 1-3
Publisher
Informa UK Limited
Online
2019-09-18
DOI
10.1080/15384047.2019.1665395
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit
- (2019) Alberto Dalla Volta et al. EUROPEAN UROLOGY
- Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.
- (2019) Bertrand F. Tombal et al. JOURNAL OF CLINICAL ONCOLOGY
- The liquid biopsy: towards standardisation in preparation for prime time
- (2019) Karen Page et al. LANCET ONCOLOGY
- Abiraterone acetate in the treatment of prostate cancer
- (2018) Abhimanyu Thakur et al. BIOMEDICINE & PHARMACOTHERAPY
- The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer
- (2018) Fred Saad et al. CANCER TREATMENT REVIEWS
- eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
- (2018) Neal D. Shore et al. Clinical Genitourinary Cancer
- Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program
- (2017) Oliver Sartor et al. ONCOLOGIST
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
- (2016) Fred Saad et al. LANCET ONCOLOGY
- Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment
- (2015) Michele Iuliani et al. Oncotarget
- Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data
- (2015) Thomas W. Flaig et al. Cancer Medicine
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started